Application of intravenous combined with interventional neoadjuvant chemotherapy to patients with StageIIIA non-small-cell lung cancer

Objective To discuss the available mode of neoadjuvant chemotherapy in patients with StageⅢA non-small-cell lung cancer.Methods Ninty-eight patients with StageⅢA non-small-cell lung cancer were divided into three groups. Group A of 32 cases received one course systemic intravenous chemotherapy and another course bronchial arterial infusion followed by surgical resection. Group B of 34 cases received two courses intravenous chemotherapy before surgery, and Group C (control group) of 32 cases received surgery only. Results The release rate (RR) of patients in Group A was 81.3% which was significantly higher than that in Group B (61.8%) (p0.05). The resection rate in Group A and B was 100% and 94.1% respectively, both higher than that of the control group (78.1%) (p0.05). The simplicity lobectomy rate in Group A (68.8%) was remarkablely higher than that in Group B (48.4%): p0.05. Significant difference of the amount of bleeding during pero-operative period was observed between Group A and C (435±55ml vs 325±70ml, p0.05), B and C (460±65ml vs 325±70ml, p0.05). The incidence of cardiac arrhythimia in Group A was lower than that in Group B. The 1-year survival rate was 85.2% (23/27) in Group A, which was significantly higher than that in Group B 68.9% (20/29) p0.05 and Group C 59.2% (16/27), p0.01. The 3-year survival rate in Group A was 64.7% (11/17), similar to that in Group B 61.1% (11/18). The 1-year and 3-year survival rates in neoadjvuant chemotherapy groups were higher than that of the control group 38.9% (7/18) (p0.01). Conclusion Intravenous combined with interventional neoadjuvant chemotherapy is a safe and effective mode in the treating StageⅢA non-small-cell lung cancer.